奧園(03883.HK):近九成房地產項目按計劃進行 逾200億人幣現有境內融資期限獲延長
中國奧園(03883.HK)公布,目前集團近九成房地產項目按計劃及進度進行,將繼續確保項目竣工交付。另集團上月與綠城管理簽署戰略合作暨廣州雲和公館代建協定,內容有關綠城管理品牌、管理和資源輸出,及項目代建等若干安排。
公司指,保持與其境內及境外債權人進行建設性對話。目前已與若干境內金融機構訂立安排延長本金逾人民幣200億元現有境內融資安排的期限,另有其他境內融資安排展期工作已與其境內債權人進入協商階段。
鑒於集團面臨的流動資金問題,集團指正在積極與潛在投資者討論有關資本重組的事宜,作為實施債務重組的一部分,並已委聘畢馬威企業諮詢(中國)作為主要財務顧問。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.